Skip to main content
Equibles
ETON logo

ETON · Eton Pharmaceuticals, Inc. · Metrics

Track ETON — free

Use ETON with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ETON.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$50.72 -0.23 (-0.45%) Play latest call Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.46B
Shares
28.58M
Volume · Nov 4 375.17K Avg daily vol (3M) 561.49K

ETON metrics

88 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$50.72
Market cap
$1.46B

Price action

20 metrics
Price change (1W)
-0.4%
Price change (30D)
-8.4%
Price change (3M)
+11.2%
Price change (6M)
+67.7%
Price change (YTD)
+201.3%
Price change (1Y)
+183.7%
Trailing year
Price change (5Y)
+680.2%
52-week high
$64.43
52-week low
$14.35
Change from 52-week high
-20.9%
Change from 52-week low
+255.1%
Annualized volatility
71.3%
Annualized volatility (3M)
100.0%
Beta
0.3
RSI (14D)
44.3
Price vs SMA 50
-8.2%
Price vs SMA 200
+41.3%
Avg volume (3M)
560,980
Relative volume
0.6
Average dollar volume
$31.09M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
28.58M

Valuation

12 metrics
P / E (TTM)
114.8
Trailing earnings · reciprocal yield 0.9%
PEG ratio
—
EV / revenue
13.8×
reciprocal yield 7.2%
EV / EBITDA
69.9×
reciprocal yield 1.4%
EV / EBIT
89.4×
reciprocal yield 1.1%
P / sales
13.8×
reciprocal yield 7.3%
P / book
31.3
reciprocal yield 3.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
96.2
reciprocal yield 1.0%
Earnings yield
0.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
6.6×
reciprocal yield 15.2%
EV / revenue historical average (5Y)
5.5×
reciprocal yield 18.0%
EV / EBIT historical average (3Y)
163.9×
reciprocal yield 0.6%
EV / EBIT historical average (5Y)
163.9×
reciprocal yield 0.6%
EV / EBITDA historical average (3Y)
202.7×
reciprocal yield 0.5%
EV / EBITDA historical average (5Y)
193.4×
reciprocal yield 0.5%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
57.9%
Operating margin
15.4%
Trailing 12 months
Net margin
12.0%
Gross profit (TTM)
$61.10M
Operating profit (TTM)
$16.31M
Net income (TTM)
$12.69M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
0.5%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.97

Growth

11 metrics
Revenue growth YoY
+98.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$105.59M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+21.9%
Year over year · more shares
Revenue CAGR (3Y)
+55.5%
Revenue CAGR (5Y)
+359.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+28.7%
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
27.2%
Return on assets
11.0%
Debt / equity
0.6
Current ratio
1.5
EBITDA (TTM)
$20.85M
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
0.1
Return on invested capital
34.1%
Trailing 12 months
Net cash
−$1.06M
Latest balance sheet
Cash & equivalents
$26.84M
Total assets
$115.81M
Total debt
$27.90M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$15.13M
Capital expenditures (TTM)
$403,000
R&D (TTM)
$5.76M
SG&A (TTM)
—
Stock compensation (TTM)
$5.20M
R&D / revenue
5.5%
Stock compensation / revenue
4.9%

Ownership (13F)

9 metrics
13F filers
164
13F filer change QoQ
+48
Institutional ownership
70.6%
Conviction holders (share of 13F filers)
3.0%
Crowding (high-turnover and private-fund holders)
38.6%
Private-fund adviser ownership
36.1%
Active holders' share change QoQ
+7.7%
Holder tenure
12.0
Price vs estimated holder cost
+123.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.4%

Short interest

3 metrics
Short interest
6.8%
Latest settlement · 3.3 days to cover
Days to cover
3.3d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$10.90M
Insider-sentiment score
8 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1710340 CUSIP 29772L108 13F (30d) 59 filings 59 filers Visit website Investor relations